Marks Marine Pharmacy: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Marks Marine Pharmacy?

Yes. FDA’s import refusal records list 1 refused shipment line declared as made by Marks Marine Pharmacy (Canada) whose FDA product code names semaglutide, on Feb 20, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
Canada
City in FDA records
Vancouver
FEI numbers on the lines
3004874025
Refused lines
1
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Semaglutide
Refusal dates
Feb 20, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Marks Marine Pharmacy is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Feb 20, 2026Canada61PCA72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
799-2034921-7/10003/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).1
UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

1 line from FDA files read Nov 15, 2026.